PULsecath mechanicaL Support Evaluation

Coronary Artery Disease Clinical Trial

— PULSE  

Official title:

PULsecath mechanicaL Support Evaluation (PULSE) - Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03200990
• Other study ID #: Pulse version 2.9
• Status: Completed
• Phase: N/A
• Start date: December 2016
• Est. completion date: December 31, 2019

Study information

• Verified date: March 2021
• Source: Erasmus Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to determine ventricular loading conditions during and after PulseCath® iVAC2L support, and assess its impact on specific load dependent humoral factors and cardiac enzymes. These specific patterns are so far unknown and will be evaluated invasively.

Description:

This is a mechanistic exploratory study. The objective is to determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors and cardiac enzymes will be made during and after the use of mechanical circulatory support. These specific patterns are so far unknown. Knowledge of optimal patterns may help in determining the ideal circulatory device platform.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is = 18 years;

2. Informed Consent must be signed by the patient, prior to HR-PCI;

3. The multidisciplinary heart team has reached consensus for high-risk PCI. Patients may present with left ventricular systolic dysfunction (ejection fraction =40%);

4. Anatomical criteria: Intervention to an unprotected left main coronary artery, left main equivalent or single remaining vessel; multivessel disease; intervention in a distal left main bifurcation.

Exclusion Criteria:

1. No written informed consent;

2. Left ventricular thrombus;

3. Interventricular septal defect;

4. Significant peripheral arterial disease or arterial lumen size < 6mm at the level of the common femoral artery;

5. Significant aortic valve disease (more than mild aortic stenosis/regurgitation);

6. Cardiogenic shock;

7. Previous stroke within the last 3 months;

8. Major bleeding event within last 3 months;

9. Chronic kidney disease with a GFR < 25 mL/min;

Related Conditions & MeSH terms

• Cardiogenic Shock
• Coronary Artery Disease
• Heart Failure
• Shock, Cardiogenic

Intervention

Device:
• iVAC2L pVAD
To determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.

Locations

Country	Name	City	State
France	Clinic Pasteur	Toulouse
Netherlands	Erasmus Medical Center	Rotterdam	South Holland
United Kingdom	Kings College London, St. Thomas' Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
Erasmus Medical Center

Countries where clinical trial is conducted

France,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Pressure-volume Area (PVA)	Numerical continuous variable representing the change in Myocardial Oxygen Consumption (MVO2) following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in PVA will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg.mL	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Cardiac Output	Numerical continuous variable representing the change in Cardiac Output (CO), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in CO will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: L/min	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change on the Mean Pulmonary Capillary Wedge Pressure	Numerical continuous variable representing the change in Mean Pulmonary Capillary Wedge Pressure (mPCWP), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in mPCWP will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg.	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in the PCWP v-wave	Numerical continuous variable representing the change in PCWP v-wave (vPCWP), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in vPCWP will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg.	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Mean Pulmonary Artery Pressure	Numerical continuous variable representing the change in Mean Pulmonary Artery Pressure (mPAP), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in mPAP will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg.	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Pulmonary Artery Oxygen Saturation	Numerical continuous variable representing the change in Pulmonary Artery Oxygen Saturation, also known as Mixed Oxygen Saturation (SVO2), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in SVO2 will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: %	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Right Atrial Pressure	Numerical continuous variable representing the change in Right Atrial Pressure (RAP), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in RAP will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg.	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Preload-recruitable Stroke Work	Numerical continuous variable representing the change in Preload-recruitable Stroke Work (PRSW), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in PRSW will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in the Starling Contractile Index	Numerical continuous variable representing the change in the Starling Contractile Index (SCI), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in SCI will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg/ml·s	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in End-systolic Wall Stress	Numerical continuous variable representing the change in the End-systolic Wall Stress (WSes), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in WSes will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg.	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in the first derivative of pressure over time	Numerical continuous variable representing the change in the first derivative of pressure over time (+dP/dtmax), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in +dP/dtmax will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: mmHg/s	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Systemic Vascular Resistance	Numerical continuous variable representing the change in the Systemic Vascular Resistance (SVR), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in SVR will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: (dyn·s)/(cm^(-5))	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Pulmonary Vascular Resistance	Numerical continuous variable representing the change in the Pulmonary Vascular Resistance (PVR), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in PVR will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: (dyn·s)/(cm^(-5))	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Cardiac Power Output	Numerical continuous variable representing the change in the Cardiac Power Output (CPO), following ventricular unloading. The PULSE trial will measure in real-time how discrepant this measurement can be when resulting from continuous or pulsatile flow ventricular assist devices. This is not a time-to-event outcome: the change in CPO will be obtained from real-time data collected during the intervention. The time frame will be the time of the Intervention. Unit: Watts	From the beginning of the PCI until its conclusion. This period can be variable and is estimated in 40 to 270 minutes.
Secondary	Change in Hematocrit	Numerical continuous variable. Change in Hematocrit (Ht) as an indicative of bleeding or hemolysis. Unit: %	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in Hemoglobin	Numerical continuous variable. Change in Hemoglobin (Hb) as an indicative of bleeding or hemolysis. Unit: mmol/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in Platelet Count	Numerical continuous variable. Change in Platelet Count as an indicative of bleeding events. Unit: 10^9/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in haptoglobin	Numerical continuous variable. Change in haptoglobin as an indicative of hemolytic events. Unit: g/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in total and conjugated bilirubin	Numerical continuous variable. Change in total and conjugated bilirubin as an indicative of hemolytic events. Unit: umol/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in lactate dehydrogenase	Numerical continuous variable. Change in lactate dehydrogenase as an indicative of hemolytic events. Unit: U/L.	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in hs-troponin	Numerical continuous variable. Change in hs-troponin as an indicative of myocardial necrosis. Unit: ng/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in creatinephosphokinase	Numerical continuous variable. Change in creatinephosphokinase (CK) as an indicative of myocardial necrosis. Unit: U/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in creatinophosphokinase MB mass assay	Numerical continuous variable. Change in creatinophosphokinase MB mass assay (CKMB-mass) as an indicative of myocardial necrosis. Unit: ug/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in N-terminal pro b-type natriuretic peptide	Numerical continuous variable. Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) as an indicative of chamber overload. Unit: pmol/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in serum lactate	Numerical continuous variable. Change in serum lactate as an indicative of hypoperfusion states. Unit: mmol/L.	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	Change in serum creatinine	Numerical continuous variable. Change in serum creatinine as an indicative of acute kidney injury. Unit: umol/L	From baseline (beginning of PCI) to immediately after the procedure and 12 hours after PCI.
Secondary	All-cause mortality	Constitutes one of the components of the MACCE composite endpoint: all-cause mortality, acute myocardial infarction, stroke or transient ischemic attack (TIA), and repeat revascularization (PCI or CABG). Time-to-event variable, measured in days.	30 days follow up
Secondary	Acute myocardial infarction	According to the "Fourth Universal Definition of Acute Myocardial Infarction". Constitutes one of the components of the MACCE composite endpoint: all-cause mortality, acute myocardial infarction, stroke or transient ischemic attack (TIA), and repeat revascularization (PCI or CABG). Time-to-event variable, measured in days.	30 days follow up
Secondary	Stroke or transient ischemic attack	As per VARC 2 definitions 2013 J Thorac Cardiovasc Surg 2013;145:6-23. Constitutes one of the components of the MACCE composite endpoint: all-cause mortality, acute myocardial infarction, stroke or transient ischemic attack (TIA), and repeat revascularization (PCI or CABG). Time-to-event variable, measured in days.	30 days follow up
Secondary	Repeat revascularization	As per ARC definition - Circulation. 2007;115:2344-2351. Constitutes one of the components of the MACCE composite endpoint: all-cause mortality, acute myocardial infarction, stroke or transient ischemic attack (TIA), and repeat revascularization (PCI or CABG). Time-to-event variable, measured in days.	30 days follow up
Secondary	Major Bleeding	Major bleeding (BARC 3 to 5), according to the BARC Bleeding Classification (BARC definitions 2011. Circulation. 2011; 123(23): 2736-47. Time-to-event variable, measured in days.	30 days follow up
Secondary	Major vascular complications	Major vascular complications (e.g.: arteriovenous fistula, limb ischemia), as per VARC-2 definitions (VARC 2 definitions 2013, J Thorac Cardiovasc Surg 2013;145:6-23) . Time-to-event variable, measured in days.	30 days follow up
Secondary	Acute renal dysfunction	Acute renal dysfunction (AKIN 1 or above), using the AKIN Classification as described in the VARC-2 definitions (VARC 2 definitions 2013 J Thorac Cardiovasc Surg 2013;145:6-23).	30 days follow up
Secondary	Increase in Aortic regurgitation	Increase in aortic regurgitation by more than one grade (TTE). Binary outcome obtained at the second echocardiogram, performed at discharge.	30 days follow up
Secondary	Severe hypotension	Severe hypotension (MAP < 60mmHg for more than 10 minutes despite fluid resuscitation or use of vasoactive amines to maintain MAP = 60 mm Hg), or shock, defined based on the definition from the SHOCK trial (1) SBP = 90mmHg for at least 30 minutes, (2) Need for vasopressors to maintain SBP > 90mmHg; (3) evidence of end-organ hypoperfusion; (4) Evidence of elevated filling pressures. A similar concept has been applied in the BCIS-1 study to measure procedural instability (JAMA. 2010;304(8):867-874).	First 48 hours after the start of PCI.
Secondary	Ventricular arrhythmias	VT requiring cardioversion and / or need for CPR. Binary outcome, VF at anytime during follow up. Time-to-event analysis, measured in days.	30 days follow up
Secondary	Angiographic failure	Angiographic failure/ procedural failure, as defined in the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention Circulation. 2011;124:e574-e651): post PCI TIMI flow < III, residual stenosis (>50% post-balloon or > 10% post stenting), or presence of thrombus, side branch loss or flow limiting dissection. It is a binary outcome (yes/no answer). No time-to-event analysis will be applied.	Assessed at the end of the PCI. This time point (end of PCI) can be variable and is estimated in 40 to 270 minutes after the beginning of the procedure.
Secondary	Time of hospitalization	Time to hospital discharge (in days).	30 days follow up
Secondary	Change in Left ventricular ejection fraction	Numerical continuous variable. Change in LVEF measured by trans-thoracic echocardiography at baseline and discharge. Not a time-to-event variable. Unit: %	From baseline (beginning of PCI) to the moment of discharge, assessed up to 30 days.